Methylation level of Rap1GAP and the clinical significance in MDS

Ding,Wen‑Jing; Yang,Yi; Chen,Zi‑Xing; Wang,Yuan‑Yuan; Dong,Wan‑Li; Cen,Jian‑Nong; Qi,Xiao‑Fei; Jiang,Feng; Chen,Su‑Ning

doi:10.3892/ol.2018.9503

Methylation level of Rap1GAP and the clinical significance in MDS

Authors:
- Wen‑Jing Ding
- Yi Yang
- Zi‑Xing Chen
- Yuan‑Yuan Wang
- Wan‑Li Dong
- Jian‑Nong Cen
- Xiao‑Fei Qi
- Feng Jiang
- Su‑Ning Chen
View Affiliations

Affiliations: Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, Jiangsu 215006, P.R. China
Published online on: September 26, 2018 https://doi.org/10.3892/ol.2018.9503
Pages: 7287-7294

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies on the pathogenesis of myelodysplastic syndrome (MDS) have identified multiple associated gene mutations, including mutations of tetmethylcytosinedioxygenase 2, isocitrate dehydrogenase [NADP(+)] 1 cytosolic, isocitrate dehydrogenase [NADP(+)] 2 mitochondrial and additional sex combs like 1 transcriptional regulator, all of which may be considered epigenetic regulators. Furthermore, mutations of RAS type GTPase family genes have been identified in 10‑15% patients with MDS. The authors' previous study on the gene expression profile of cluster of differentiation 34+ cells using microarray analysis identified elevated expression of RAP1GTPase activating protein 1 (Rap1GAP) in patients with MDS compared with that in non‑malignant blood diseases (NM) control group. To further investigate the mechanism of increased Rap1GAP expression, the methylation pattern of the promoter of this gene was determined in 86 patients with MDS (n=29), acute myeloid leukemia (AML) (n=31) or NM (n=26) using bisulfite‑specific polymerase chain reaction and DNA sequencing. The results demonstrated that the methylation of Rap1GAP occurred in all 29 patients with MDS at multiple CpG sites. The methylation level of Rap1GAP in patients with MDS was decreased compared with that in patients with NM. Significant differences at 4CpG sites (5,7,8 and 12) of Rap1GAP promoter were identified between MDS and NM. Furthermore, based on the present clinical records of the patient cohort, the methylation status of Rap1GAP promoter did not appear to be associated with the clinicopathological characteristics of patients with MDS, including age, gender and International Prognosis Score System. The difference in methylation level at CpG site 8 of Rap1GAP promoter was identified to be significantly increased in patients with MDS‑refractory anemia with ring sideroblasts compared with that in the MDS‑refractory cytopenia with multilineage dysplasia or MDS‑unclassified groups. The results of the present study suggest that patients with MDS exhibit a lower overall methylation level within Rap1GAP promoter compared with patients with NM or AML. In addition, the methylation level at the four identified CpG sites can distinguish between MDS and NM.

View Figures

View References

1	Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, O'Keefe C, Sekeres M, Saunthararajah Y and Maciejewski JP: Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood. 113:1315–1325. 2009. View Article : Google Scholar : PubMed/NCBI
2	Issa JP: The myelodysplastic syndrome as a prototypical epigenetic disease. Blood. 121:3811–3817. 2013. View Article : Google Scholar : PubMed/NCBI
3	Lindsley RC and Ebert BL: The biology and clinical impact of genetic lesions in myeloid malignancies. Blood. 122:3741–3748. 2013. View Article : Google Scholar : PubMed/NCBI
4	Ushijima T: Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer. 5:223–231. 2005. View Article : Google Scholar : PubMed/NCBI
5	Ika SA, Qi XF and Chen ZX: Protein RAP1GAP in human myelodysplastic syndrome detected by flow cytometry and its clinical relevance. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 17:612–617. 2009.PubMed/NCBI
6	Qi X, Chen Z, Qian J, Cen J and Gu M: Expression of Rap1GAP in human myeloid disease following microarray selection. Genet Mol Res. 7:379–87. 2008. View Article : Google Scholar : PubMed/NCBI
7	Greenberg P, Cox C, Lebeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 89:2079–88. 1997.PubMed/NCBI
8	Keller S, Angrisano T, Florio E, Pero R, Decaussin-Petrucci M, Troncone G, Capasso M, Lembo F, Fusco A and Chiariotti L: DNA methylation state of the galectin-3 gene represents a potential new marker of thyroid malignancy. Oncol Lett. 6:86–90. 2013. View Article : Google Scholar : PubMed/NCBI
9	Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U and Salih HR: Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk Myelodysplastic Syndrome (MDS) ineligible for intensive chemotherapy: Final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 29:1987–1996. 2011. View Article : Google Scholar : PubMed/NCBI
10	Deschler B, de Witte T, Mertelsmann R and Lübbert M: Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: Problems and approaches. Haematologica. 91:1513–1522. 2006.PubMed/NCBI
11	Breccia M: From FAB to 2008 WHO classification: The wide heterogeneity of refractory anemia subtype among different countries. Leuk Res. 34:967–968. 2010. View Article : Google Scholar : PubMed/NCBI
12	Nilsson L, Astrand-Grundström I, Arvidsson I, Jacobsson B, Hellström-Lindberg E, Hast R and Jacobsen SE: Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: Evidence for involvement at the hematopoietic stem cell level. Blood. 96:2012–2021. 2000.PubMed/NCBI
13	Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 89:2079–2088. 1997.PubMed/NCBI
14	Hasle H, Baumann I, Bergsträsser E, Fenu S, Fischer A, Kardos G, Kerndrup G, Locatelli F, Rogge T, Schultz KR, et al: The international prognostic scoring system (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). Leukemia. 18:2008–2014. 2004. View Article : Google Scholar : PubMed/NCBI
15	Stork PJ and Dillon TJ: Multiple roles of Rap1 in hematopoietic cells: Complementary versus antagonistic functions. Blood. 106:2952–2961. 2005. View Article : Google Scholar : PubMed/NCBI
16	Zhang L, Chenwei L, Mahmood R, van Golen K, Greenson J, Li G, D'Silva NJ, Li X, Burant CF, Logsdon CD and Simeone DM: Identification of a putative tumor suppressor gene Rap1GAP in pancreatic cancer. Canc Res. 66:898–906. 2006. View Article : Google Scholar
17	Tsygankova OM, Wang H and Meinkoth JL: Tumor cell migration and invasion are enhanced by depletion of Rap1 GTPase-activating protein (Rap1GAP). J Biol Chem. 288:24636–24646. 2013. View Article : Google Scholar : PubMed/NCBI
18	Zuo H, Gandhi M, Edreira MM, Hochbaum D, Nimgaonkar VL, Zhang P, Dipaola J, Evdokimova V, Altschuler DL and Nikiforov YE: Downregulation of Rap1GAP through epigenetic silencing and loss of heterozygosity promotes invasion and progression of thyroid tumors. Cancer Res. 70:1389–1397. 2010. View Article : Google Scholar : PubMed/NCBI
19	Zheng H, Gao L, Feng Y, Yuan L, Zhao H and Cornelius LA: Down-regulation of Rap1GAP via promoter hypermethylation promotes melanoma cell proliferation, survival, and migration. Cancer Res. 69:449–457. 2009. View Article : Google Scholar : PubMed/NCBI
20	Maffei R, Bulgarelli J, Fiocari S, Bertoncelli L, Martinelli S, Guarnotta C, Castelli I, Deaglio S, Debbia G, De Biasi S, et al: The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. Haematologica. 98:1115–1123. 2013. View Article : Google Scholar : PubMed/NCBI
21	Potla U, Ni J, Vadaparampil J, Yang G, Leventhal JS, Campbell KN, Chuang PY, Morozov A, He JC, D'Agati VD, et al: Podocyte-specific Rap1GAP expression contributes to focal segmental glomerulosclerosis-associated glomerular injury. J Clin Invest. 124:1757–1769. 2014. View Article : Google Scholar : PubMed/NCBI
22	Qiu T, Qi X, Cen J and Chen Z: Rap1GAP alters leukemia cell differentiation, apoptosis and invasion in vitro. Oncol Rep. 28:622–628. 2012. View Article : Google Scholar : PubMed/NCBI
23	Kim WJ, Gersey Z and Daaka Y: Rap1GAP regulates renal cell carcinoma invasion. Cancer Lett. 320:65–71. 2012. View Article : Google Scholar : PubMed/NCBI
24	Tsujioka T, Yokoi A, Uesugi M, Kishimoto M, Tochigi A, Suemori S, Tohyama Y and Tohyama K: Effects of DNA methyltransferase inhibitors (DNMTIs) on MDS-derived cell lines. Exp Hematol. 41:189–197. 2013. View Article : Google Scholar : PubMed/NCBI